170 related articles for article (PubMed ID: 37963297)
1. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
2. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
3. The effect of the weather on pulmonary exacerbations and viral infections among adults with cystic fibrosis.
Flight WG; Bright-Thomas RJ; Sarran C; Mutton KJ; Morris J; Webb AK; Jones AM
Int J Biometeorol; 2014 Nov; 58(9):1845-51. PubMed ID: 24452385
[TBL] [Abstract][Full Text] [Related]
4. Course of Illness after Viral Infection in Indian Children with Cystic Fibrosis.
Gulla KM; Balaji A; Mukherjee A; Jat KR; Sankar J; Lodha R; Kabra SK
J Trop Pediatr; 2019 Apr; 65(2):176-182. PubMed ID: 29893951
[TBL] [Abstract][Full Text] [Related]
5. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis.
Flight WG; Bright-Thomas RJ; Tilston P; Mutton KJ; Guiver M; Morris J; Webb AK; Jones AM
Thorax; 2014 Mar; 69(3):247-53. PubMed ID: 24127019
[TBL] [Abstract][Full Text] [Related]
6. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
7. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
8. Respiratory viruses: What is their role in acute exacerbations in children with cystic fibrosis?
Hizal M; Yalcin E; Alp A; Ozden M; Karakaya J; Eryilmaz Polat S; Tugcu G; Dogru D; Ozcelik U; Kiper N
Pediatr Pulmonol; 2020 Jul; 55(7):1646-1652. PubMed ID: 32227679
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Goss CH; Heltshe SL; West NE; Skalland M; Sanders DB; Jain R; Barto TL; Fogarty B; Marshall BC; VanDevanter DR; Flume PA;
Am J Respir Crit Care Med; 2021 Dec; 204(11):1295-1305. PubMed ID: 34469706
[No Abstract] [Full Text] [Related]
10. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
11. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
[TBL] [Abstract][Full Text] [Related]
12. Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis.
Carter SC; Franciosi AN; O'Shea KM; O'Carroll OM; Sharma A; Bell A; Keogan B; O'Reilly P; Coughlan S; Law SM; Gray RD; Hisert KB; Singh PK; Cooke G; Grogan B; De Gascun CF; Gallagher CG; Nicholson TT; Quon BS; McKone EF
Ann Am Thorac Soc; 2022 Nov; 19(11):1818-1826. PubMed ID: 35713619
[No Abstract] [Full Text] [Related]
13. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
14. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
[TBL] [Abstract][Full Text] [Related]
15. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
16. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
17. Antipseudomonal treatment decisions during CF exacerbation management.
VanDevanter DR; West NE; Sanders DB; Skalland M; Goss CH; Flume PA; Heltshe SL
J Cyst Fibros; 2022 Sep; 21(5):753-758. PubMed ID: 35466039
[TBL] [Abstract][Full Text] [Related]
18. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation.
Etherington C; Naseer R; Conway SP; Whitaker P; Denton M; Peckham DG
J Cyst Fibros; 2014 Jan; 13(1):49-55. PubMed ID: 23891398
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Association between
O'Dea AL; Feng R; Glaser LJ; Kubrak C; Rubenstein RC; Dorgan DJ; Hadjiliadis D; Kawut SM; Hong G
Ann Am Thorac Soc; 2023 Jul; 20(7):984-992. PubMed ID: 36800434
[No Abstract] [Full Text] [Related]
20. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
VanDevanter DR; Morris NJ; Konstan MW
J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
